The locus nfxD, which contributes to high-level quinolone resistance in Escherichia coli KF111b (gyrA r nfxB nfxD), is only expressed in the presence of a gyrA mutation, and maps to the region of the parC and parE genes, was outcrossed into strain KF130, creating strain DH161 (gyrA r nfxD). DNA sequence analysis of DH161 revealed no changes in the topoisomerase IV parC quinolone resistance-determining region but did identify a single T-to-A mutation in parE at codon 445, leading to a change from Leu to His. Full-length cloned parE ؉ partially complemented the resistance phenotype in KF111b and DH161, but did not complement the resistance phenotype in strain KF130 (gyrA r ). No complementation was seen with cloned, truncated parE ؉ . To confirm these findings, gyrA r was first outcrossed from KF130 into E. coli W3110parE10 [parE temperature sensitive(Ts)] and KL16. The transduced strains KL16 and W3110parE10 were subsequently transformed with plasmids containing cloned parE from DH161 or KL16. Cloned parE from DH161 increased norfloxacin resistance in the parE(Ts) background twofold at 30؇C and fourfold at 42؇C compared to those for cloned parE from KL16. The same experiment with a non-Ts background revealed a twofold increase in the norfloxacin MIC at both 30 and 42؇C. These data identify the nfxD conditional resistance locus as a mutant allele of parE. This report is the first of a quinolone-resistant parE mutant and confirms the role of topoisomerase IV as a secondary target of norfloxacin in E. coli.
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DNA gyrase, a type 2 topoisomerase, is composed of two subunits encoded by gyrA and gyrB and functions in Escherichia coli in the maintenance of chromosomal superhelical tension via the introduction of negative supercoils (15, 21) . Fluoroquinolones target DNA gyrase by locking the enzyme in a cleavable complex with DNA (23) , ultimately leading to cell death (3) . Single-step mutations in DNA gyrase effect a 100-fold increase in the MICs of older quinolones such as nalidixic acid or 16-to 32-fold increases in the MICs of newer quinolones such as norfloxacin, ciprofloxacin, and ofloxacin (8) . Serial passage in media containing increasing concentrations of quinolones can select for resistant strains with multiple mutations and for which MICs are even higher.
Topoisomerase IV, an essential enzyme of E. coli, the primary function of which is chromosomal segregation following DNA replication, is composed of two subunits encoded by parC and parE, which are homologous to gyrA and gyrB of DNA gyrase, respectively (12) . Mutations in parC at positions similar to those seen in the quinolone resistance-determining region of gyrA (28, 30) have been found in highly resistant strains, but interestingly, they only appear in the presence of a primary gyrA mutation (7, 14, 16, 26) .
E. coli KL16 was serially passaged on norfloxacin, and strain KF111b was isolated. The MIC for strain KF111b is 125-fold greater than that for the parent strain (10) . It was determined that KF111b had, in addition to the expected gyrA mutation, at least two other resistance loci, termed nfxB and nfxD. Previous work in this laboratory has shown nfxB to be associated with reduced ompF expression and reductions in cellular drug accumulation (9), while nfxD mapped to the region near the parC and parE genes and was only conditionally expressed in resistant gyrA mutants (25) . Wild-type gyrA, cloned on a plasmid, fully complemented the resistance phenotype of a gyrA r nfxD double mutant (25) .
In this study, quinolone resistance above that attributable to gyrA and associated with the nfxD locus was determined to be caused by a single point mutation in the coding sequence of topoisomerase IV parE. Complementation was only partial in the presence of wild-type parE ϩ , indicating incomplete dominance over parE r . These findings were confirmed by outcrossing gyrA r into a temperature-sensitive (Ts) parE background and augmenting resistance with parE r cloned on a plasmid. Our results support topoisomerase IV as a direct but secondary target of current quinolone antimicrobial agents in E. coli.
MATERIALS AND METHODS
Bacterial strains, media, growth conditions, DNA purification, and plasmids. The E. coli strains and plasmids used in the study and their sources are described in Table 1 . Bacterial cells were grown either in Luria broth (LB) or on LB supplemented with agar. Transformed cells were always grown in the presence of ampicillin (AMP; Sigma) at 100 g/ml. Ts strains were grown at 30ЊC (permissive) or 42ЊC (nonpermissive). All other strains were grown at 37ЊC. Plasmid DNA was isolated by either the Wizard Minipreps DNA Purification System (Promega), Plasmid Midi (Qiagen), or Plasmid Maxi (Qiagen) protocols.
Determination of MICs. The MICs for plasmid complementation assays were determined by the gradient plate method. Cells were grown overnight in Mueller-Hinton (MH) broth (BBL) and were diluted to approximately 2 ϫ 10 7 CFU/ml in MH broth. Gradient plates were constructed by using a bottom layer of MH agar containing AMP (100 g/ml) and norfloxacin (Sigma) at 0, 2.5, 5, or 10 g/ml (depending on the strain to be tested) and a top layer of MH agar containing AMP (100 g/ml). Diluted cells were then streaked onto the surface with a sterile cotton swab. MICs were determined by multiplying the ratio of the total distance of growth (in millimeters from 0 g/ml) to plate length by the maximum concentration of norfloxacin per plate. All plates were freshly prepared, and assays were performed on 3 separate days. Other MICs were determined by the agar dilution method with L agar supplemented with AMP at 100 g/ml (10).
Transformation and transduction. Transformation of cells used in the gradient plate analysis was performed by the method of Chung et al. (2) , with the exception that the culture medium was supplemented with MgSO 4 (20 mM). Other transformations were performed by the method of electroporation. Approximately 5 g of plasmid DNA was added to 150 l of cells (made electrocompetent following the manufacturer's protocol; Bio-Rad) in a 0.2-cm Gene Pulser cuvette (Bio-Rad). Electrotransformation was performed in a Gene Pulser (Bio-Rad) set at 25 F, 247 kV, and 200 ⍀. Selection by both methods was on L agar supplemented with AMP (100 g/ml). P1cmclr (Table 1) transduction was performed by the method of Silhavy et al. (24) , with slight modification. Cells were grown in LB supplemented with 10 mM MgSO 4 and 10 mM CaCl 2 . Selection for transposon Tn10 was performed in the presence of tetracycline (TET; 30 g/ml) at 30ЊC.
Construction of strains DB230-1 and DB232-6. DNA from E. coli RM3691 (Table 1) was first transduced into KF130 by using bacteriophage P1cmclr. Transductants (DB130) were selected on TET and were screened for norfloxacin resistance and the ability to grow at 42ЊC. We found that 18 of 23 transductants were resistant to norfloxacin and TET and able to grow at 42ЊC, indicating 78% linkage of gyrA to transposon zei-723::Tn10. P1cmclr was grown on DB130, and lysogeny was selected by chloramphenicol. A P1cmclr lysate of DB130 was used to transduce strains W3110parE10 and KL16, creating strains DB230-1 and DB232-6, respectively. Transductants were selected on TET and were screened for quinolone resistance and temperature sensitivity.
PCR. For each allele of parE and parC, chromosomal DNA was prepared from strain KL16, DH161, or KF111b as described previously (25) . To clone parE, DNA was subjected to PCR with a 29-mer, 5Ј-GTGAATTCCGATCGTCGAT TTTCTTGGTC, and a 35-mer, 5Ј-GTGAATTCCCTTTAAACCTCAATCTCC GCCATGTC, both of which contain an EcoRI restriction site engineered into the 5Ј end. To clone parC, DNA was subjected to PCR with a 35-mer, 5Ј-GTG GATCCATGAGCGATATGGCAGAGCGCCTTGCG, and a 29-mer, 5Ј-CAG GATCCTTACTCTTCGCTATCACCGCT, both of which contain a BamHI restriction site engineered into the 5Ј end. Reactions were performed in a DNA thermal cycler with 2.0 U of Vent DNA polymerase (New England Biolabs), 1ϫ Vent DNA buffer (New England Biolabs), 2 mM MgSO 4 , 250 M (each) deoxynucleotide triphosphates, 10 l of 200 nM stock (each) oligonucleotide primer, and the bacterial DNA (final volume, 100 l). Twenty-nine cycles with the following temperature profiles were used for both reactions: 94ЊC for 2 min and 30 s, 94ЊC for 1 min, 70ЊC for 45 s, and 75ЊC for 2 min and 20 s. PCR products were either digested with EcoRI or BamHI and ligated into similarly digested pGEM7-zf(ϩ).
DNA sequence analysis. The entire KL16 and DH161 parE alleles were independently sequenced from plasmids pEN160 and pEN161, respectively, by using the ABI Fluorescent System and Taq Dye terminators (Qiagen). The following primers for parE, based on the sequence determined by Kato et al. (12) and Peng and Marians (20) , were used: in the forward reading frame, 5Ј-GTGAATTCC GATCGTCGATTTTCTTGGTC, 5Ј-GTACCGGCGGTTGAACTGAT, 5Ј-AT TGTGCCCTGGCGTTGAGA, 5Ј-TGTACCGCGCAGGACCTTAA, 5Ј-CATT TCCGCGCGTTGGTGAA, 5Ј-ATGCAGGGCGGTACCCATGTTAA, and 5Ј-TTGCCGGGCAGACGAAAGA, and in the reverse reading frame, 5Ј-CTCTC CGGATCCAAGCTTA (pEN161 only), 5Ј-GTCGCATGCTCCTCTAGA (pEN160 only), 5Ј-TCCGTCAGCGCGTAATA, 5Ј-TAAGGTCCTGCGCGGT ACAAT, 5Ј-ATGGGTACCGCCCTGCATCGTT, 5Ј-TTCATCCGGCCAGAA GT, and 5Ј-ATGCAGGCCGCCAGAGAA. Sequencing of parC was performed by the method of Sanger et al. (22) with cloned parC on plasmids pEN260, pEN261, and pEN262 and the following primers: 5Ј-GTATGCGATGTCTGA ACT and 5Ј-AAGCCACATTGCGTAACG.
RESULTS
Cloning and sequencing of parC and parE alleles. Chromosomal DNA from E. coli KL16, DH161, and KF111b was extracted, and parC was amplified by PCR as described in Materials and Methods. In all three cases a band corresponding to 2.2 kb was cut with BamHI and was cloned into pGEM7-zf(ϩ), creating plasmids pEN260, pEN261, and pEN262, respectively ( Table 1 ). The putative quinolone resistance-determining region of each of the three parC alleles, corresponding to amino acids 59 through 107, was sequenced. The parC sequence of KL16 was identical to those published previously (12, 20) , and the parC sequences of DH161 and KF111b were also identical to that of KL16 (data not shown).
Because the nfxD locus maps on the E. coli chromosome in the region of the linked parC and parE genes, we next cloned and sequenced parE from KL16 and DH161. Chromosomal DNAs from both of these strains were extracted, and parE was amplified by PCR as described in Materials and Methods. In both cases, the amplified product was a single 1.9-kb band with engineered EcoRI sites at each end. parE was cloned into the EcoRI site of pGEM7-zf(ϩ), creating plasmids pEN160 (KL16) and pEN161 (DH161) ( Table 1 ). The sequences of both strands of the entire parE gene plus approximately 50 bp upstream of parE from pEN160 and pEN161 were determined. The sequences generated were compared to each other and the published parE sequence of E. coli W3110 (12, 20) . The parE sequence of KL16 was identical to that of the published parE sequence (data not shown). When comparing parE of DH161 to that of KL16, a single T-to-A change was detected, resulting in the replacement of a leucine with a histidine at codon 445 (Fig. 1) .
Complementation of norfloxacin resistance. To determine the relationship of the parE mutation found in the nfxD mutant to the resistance conferred by the nfxD locus, we performed complementation experiments (Table 2) . nfxD-containing and control strains were transformed with a plasmid containing the full-length parE ϩ gene (pET3c-parE). As controls, strains were FIG. 1. Partial nucleotide sequences of cloned parE from KL16 and DH161 compared to that of W3110 parE (12, 20) . The single amino acid difference at codon 445 is indicated in boldface. also transformed with plasmids containing a truncated (pET3c-parEt) parE ϩ and full-length (pET3c-parC) and truncated (pET3c-parCt) parC ϩ genes. For wild-type strain KL16, there were no differences in the MIC of norfloxacin among transformants containing any of the four plasmids. In contrast, MICs for KF111b and DH161, nfxD gyrA mutants containing the parE(Leu445His) allele, were reduced 2.6-and 2.1-fold, respectively, when transformants with pET3c-parE were compared with transformants with pET3c-parEt. There was, however, also a smaller (1.6-fold) but reproducible reduction in the MIC of norfloxacin when the pET3c-parE transformant of KF130 gyrA was compared with the pET3c-parEt transformant of the same strain, suggesting that the effect of pET3c-parE was not completely specific for the nfxD mutants. The pET3c-parC plasmids had even less of an effect on the MIC of norfloxacin for the mutant strains. Plasmid pET3c-parEt or pET3c-parE was used to transform E. coli W3110parE10 [parE (Ts)], and plasmid pET3-parCt or pET3c-parC was used to transform E. coli EJ812 [parC(Ts)]. We confirmed that pET3c-parE and pET3c-parC complemented the temperature sensitivities of W3110parE10 and EJ812, respectively (data not shown), and thus were expressing their respective functional subunits. In contrast, pET3c-parEt did not complement the growth of W3110parE10 at 42ЊC, indicating that it was a suitable control plasmid for comparison with pET3c-parE in the resistance complementation experiments.
Contribution of parE(Leu445His) to quinolone resistance. Because of possible nonspecific effects in the parE ϩ complementation experiments, we attempted to define further the role of parE(Leu445His) in the resistance of nfxD mutants by demonstrating the ability of this parE allele to confer resistance in a parE(Ts) mutant. Because nfxD resistance is expressed only in a gyrA r background, it was first necessary to construct strain DB230-1 gyrA r parE(Ts) as described in Materials and Methods. The parE ϩ gene was cloned from strain KL16(pEN160), and the parE(Leu445His) allele was cloned from DH161(pEN161) in plasmid pGEM7-zf(ϩ ), and transformants were tested for their resistance to norfloxacin at permissive and nonpermissive temperatures (Table 3) . At the permissive temperature, pEN161 caused a twofold increase in the norfloxacin MIC for DB230-1 [gyrA parE(Ts)]. At the nonpermissive temperature, however, there was a fourfold increase in the MIC of norfloxacin for a pEN161 transformant relative to that for the pEN160 transformant of DB230-1. Furthermore, both plasmids complemented the thermosensitive phenotype of the parE(Ts) strains DB230-1 and W3110parE10, but only in DB230-1 did pEN161 cause an increase in resistance, consistent with the conditional expression of the nfxD resistance phenotype previously reported. Interestingly, there was also an apparent slight effect of pEN161 in DB232-6, increasing resistance twofold at both temperatures. For all strains, growth at the higher temperature was associated with a two-to fourfold increase in the norfloxacin MIC.
DISCUSSION
E. coli KF111b was selected for quinolone resistance on increasing concentrations of norfloxacin, and the MIC for strain KF111b was 125-fold greater than that for the parent strain, KL16 (10) . Previous analysis of KF111b in this laboratory revealed mutations in gyrA and nfxB, a locus affecting expression of OmpF, which together accounted for only a portion of the total resistance profile of KF111b (9, 10) . A third resistance locus was subsequently mapped to 65 min on the E. coli chromosome by linkage to zgh-3075::Tn10 and was termed nfxD (25) . The parC and parE genes encoding topoisomerase IV also map in this region of the E. coli chromosome (12) , and thus, nfxD was considered to be a possible mutant allele of parC or parE. nfxD was the first quinolone resistance locus to be found to be conditionally expressed in gyrA mutants. Subsequently, several groups have identified mutations in parC in strains with gyrA r mutations (7, 14, 16) . parC resistance mutations were also found to be expressed only in the presence of gyrA r mutations (14) . Our sequence analysis of cloned parC from DH161 and KF111b included the region predicted to contain resistance mutations, based on analogy to gyrA (12, 20) and in which previously reported parC mutations were identified. No parC mutation was found, however. The entire parE gene from DH161 and KL16 was then sequenced, and a single change from T to A was detected in codon 445, encoding a change from Leu to His. Several lines of evidence support the role of parE (Leu445His) in quinolone resistance in KF111b and DH161. First, nfxD was conditionally outcrossed from KF111b via zgh-3075::Tn10 into KF130 (gyrA r ) [creating strain DH161 (gyrA r nfxD)] but could not be outcrossed into KL16. Furthermore, cloned gyrA ϩ fully complements norfloxacin resistance in DH161 (25) . Our previous findings led us to the conclusion that nfxD is silent in the absence of a gyrA r mutation, a finding which is consistent with that seen for parC quinolone resistance mutations (14) . Second, only full-length parE ϩ , cloned on a plasmid, partially complemented nfxD in KF111b and DH161. A slight reduction was, however, also seen in the MICs for KF130 and DB230-1, but not that for KL16 transformed with full-length parE ϩ , compared to those for cells transformed with truncated parE. Thus, in the presence of gyrA r , plasmidencoded ParE may have effects on cellular growth or other factors that confound possible specific complementation of parE(Leu445His) by parE ϩ . Third, to clarify the role of parE(Leu445His) in resistance, cloned parE from DH161 or KL16 was transformed into a parE(Ts) background with (in DB230-1) and without (in W3110parE10) a gyrA r mutation. At the permissive temperature, a twofold increase in the MIC of norfloxacin was seen for strains with the DB230-1 and DB232-6 (gyrA r ) backgrounds with parE r compared to the MICs for parE ϩ or the plasmid vector control strains. At the nonpermissive temperature in the DB230-1 background, a further increase in the MIC of norfloxacin to fourfold was seen for strains with parE r compared to that for strains with parE ϩ . These results are consistent with the codominance of the plasmid-encoded alleles when both resistant and susceptible alleles are fully functional. The absence of an effect of parE r in strains W3110parE10 and KL16 at either temperature is further consistent with the dependence of resistance on a mutant gyrA r gene, as was the resistance seen for the nfxD locus.
The Leu445His mutation that we have identified is in the region of ParE that is homologous to the region of GyrB in which quinolone resistance mutations have been found and which is thought to be a domain involved in the interactions between the GyrB and GyrA subunits (11, 17, 29) . This region is highly conserved between the ParE and GyrB subunits. Of the 52 amino acids aligned between positions 395 and 446 of ParE and the homologous positions 401 and 452 of GyrB, 37 are identical and another 6 are conservatively substituted, representing together 83% of the amino acids in the region. This region is also one of those most highly conserved among ParE subunits of different species, including Staphylococcus aureus (4) and Streptococcus pneumoniae (19) . Quinolone resistance mutations in E. coli GyrB have been found in the middle portion of this region at positions 426 (Asp is replaced by Asn) and 447 (Lys is replaced by Glu). A possible quinolone resistance mutation in Salmonella typhimurium GyrB has been described, but it is located outside the conserved region at position 463 (Ser is replaced by Tyr) (5) . No changes in the residues in ParE (Asp420 and Lys441, respectively) homologous to those in GyrB (Asp426 and Lys 447) were found in the nfxD mutant. Our sequence alignment revealed an alanine at position 457 in ParE (unchanged in the nfxD mutant) which corresponded to Ser463 in GyrB. The amino acid at position 445 which is mutated in ParE r is located at the C-terminal side of the conserved domain and is retained in GyrB as a wild-type Leu at position 451. Interestingly, the substitution of His for Leu at position 445 in ParE r produces a change from a neutral to a positive charge. The electrostatic effects of a similar positive charge generated by the Asp426Asn resistance mutation in GyrB have been postulated to cause resistance by repulsion of the positively charged piperazinyl group of fluoroquinolones (29) . Thus, our findings are consistent with such a model that has now been extended to resistance mediated by altered ParE. Recently, the crystal structure of part of yeast topoisomerase II has been determined, and Leu480 of this enzyme, which corresponds to Leu445 of ParE, is distant from the active-site tyrosine and the amino acids that are homologous to those in GyrA that, when mutated, cause quinolone resistance (1) . Therefore, we must also consider more strongly other plausible models in which resistance is mediated by altered ParE or GyrB by conformational changes in the respective cognate subunits that secondarily alter the binding of fluoroquinolones to putative contact points on ParC or GyrA, which are in proximity to the active-site tyrosine (1) . In either case, our findings provide further support for the notion that the sites and functional requirements for the interactions of quinolones with DNA gyrase and topoisomerase IV are similar.
The apparent codominance of the plasmid-encoded parE ϩ or parE(His445) over their chromosomal counterparts in merodiploids is similar to that seen with multicopy alleles of either parC ϩ or parC r (14) . These findings are in contrast to the dominance of gyrA ϩ over both gyrA r (6) and parE(His445) (25) and the dominance of gyrB ϩ over gyrB r (17) . These differences imply that although the structural requirements for binding of quinolones to gyrase-DNA complexes or topoisomerase IV-DNA complexes may be similar, the consequences of these interactions differ. The finding of codominance of parC ϩ and parC ϩ based on gene dosage led others to postulate that DNA strand breaks generated by the interactions of quinolones with sensitive topoisomerase IV may be more readily repaired than those generated by the interaction of quinolones with DNA gyrase, because topoisomerase IV, in contrast to DNA gyrase, acts at a distance from the replication fork (14) . This model then implies that movement of a replication fork through a topoisomerase-quinolone-generated DNA break generates a lethal or poorly repairable lesion or is necessary to trigger subsequent lethal events. Additional factors, however, may be involved in the interaction of quinolones with topoisomerase IV in other species. In S. aureus, in particular, these differences include the following: (i) topoisomerase IV is the principal quinolone target (4, 18, 27) , (ii) the dominance of grlA (parC) by gene dosage requires the additional presence of plasmidencoded grlB (parE) (27) , and (iii) grlA (parC) single mutants are less effectively killed compared to the effectiveness with which gyrA single mutants are killed (18) .
We conclude from these results that the norfloxacin resistance locus nfxD is a mutant allele of the parE gene of E. coli topoisomerase IV and that there is, like for parC, codominance of parE alleles encoded on a plasmid. In addition, these findings provide further support for the concept that topoisomerase IV is a secondary target of current quinolones in E. coli.
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